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A B S T R A C T   
The renin-angiotensin system (RAS) plays a major role in COVID-19. Severity of several inflammation-related 
diseases has been associated with autoantibodies against RAS, particularly agonistic autoantibodies for angio-
tensin type-1 receptors (AA-AT1) and autoantibodies against ACE2 (AA-ACE2). Disease severity of COVID-19 
patients was defined as mild, moderate or severe following the WHO Clinical Progression Scale and deter-
mined at medical discharge. Serum AA-AT1 and AA-ACE2 were measured in COVID-19 patients (n = 119) and 
non-infected controls (n = 23) using specific solid-phase, sandwich enzyme-linked immunosorbent assays. Serum 
LIGHT (TNFSF14; tumor necrosis factor ligand superfamily member 14) levels were measured with the corre-
sponding assay kit. At diagnosis, AA-AT1 and AA-ACE2 levels were significantly higher in the COVID-19 group 
relative to controls, and we observed significant association between disease outcome and serum AA-AT1 and 
AA-ACE2 levels. Mild disease patients had significantly lower levels of AA-AT1 (p < 0.01) and AA-ACE2 (p <
0.001) than moderate and severe patients. No significant differences were detected between males and females. 
The increase in autoantibodies was not related to comorbidities potentially affecting COVID-19 severity. There 
was significant positive correlation between serum levels of AA-AT1 and LIGHT (TNFSF14; rPearson = 0.70, p <
0.001). Both AA-AT1 (by agonistic stimulation of AT1 receptors) and AA-ACE2 (by reducing conversion of 
Angiotensin II into Angiotensin 1-7) may lead to increase in AT1 receptor activity, enhance proinflammatory 
responses and severity of COVID-19 outcome. Patients with high levels of autoantibodies require more cautious 
control after diagnosis. Additionally, the results encourage further studies on the possible protective treatment 
with AT1 receptor blockers in COVID-19.   
1. Introduction 
Many recent studies have highlighted the major role of renin- 
angiotensin system (RAS) in severity of COVID-19 [1–3]. Angiotensin 
converting enzyme 2 (ACE2) plays a key role in the process and it is 
usually considered that ACE2 acts as a double-edged sword [4,5]. First, 
ACE2 transforms components of the pro-inflammatory RAS axis such as 
angiotensin I (Ang I) and particularly Ang II into components of the 
anti-inflammatory RAS axis such as Ang1-9 and particularly Ang 1–7. 
Ang II acts on angiotensin type 1 (AT1) receptors and activates the 
NADPH-oxidase complex producing superoxide and promoting cell 
pro-oxidative and pro-inflammatory responses [6,7], while Ang 1–7 acts 
on Mas and Mas-related receptors promoting cell antioxidative and 
anti-inflammatory responses. Therefore, an increase in ACE2 activity is 
essential to balance the RAS towards the anti-inflammatory response. 
Consistent with this, the protective effects of ACE2 and its product 
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Ang1-7 against experimental lung injuries have previously been 
demonstrated [8]. Second, ACE2 is also the entry receptor for the virus 
[9], and upregulation of ACE2 expression may enhance cell infection. 
Third, both ACE2 functions interact each other, since SARS-CoV-2 
binding to ACE2 decreases the levels of ACE2 at the cell surface [10, 
11], thus shifting the RAS balance towards the pro-inflammatory Ang 
II/AT1 axis, which leads to inflammation, fibrosis and progression of 
disease severity. 
It is known that differences in immunological responses in different 
patients play a major role in progression and severity of COVID-19. 
Progression and severity of several inflammation-related processes 
have been associated with the presence of autoantibodies against major 
components of the RAS. Particularly, the presence of autoantibodies for 
AT1 receptors (AA-AT1), which act as AT1 receptor agonists, enhanced 
the proinflammatory RAS activity in several tissues and processes [12]. 
In addition, the presence of autoantibodies against ACE2 (AA-ACE2) has 
also been detected in several processes, and AA-ACE2 have been 
involved in progression of inflammation [13]. ACE2 autoantibodies 
have been related to inhibition of ACE2 function [13], which decreases 
the anti-inflammatory arm activity and shift the balance towards the 
proinflammatory RAS. The mechanisms responsible for generation of 
the above-mentioned autoantibodies have not been totally clarified. 
However, the increase in levels of cytokines such as IL-6 and TNF-α [14, 
15], and particularly TNFSF14 (tumor necrosis factor ligand superfamily 
member 14, LIGHT) [16] has been associated to the increase in gener-
ation of AA-AT1. An increase in levels of pro-inflammatory cytokines 
also plays a major role in severity of COVID-19 outcome. However, it is 
not known whether these autoantibodies (AA-AT1, AA-ACE2) are 
increased in COVID-19 patients and whether the levels of RAS autoan-
tibodies could be associated to progression of COVID-19 severity. In the 
present study, we investigated the levels of AA-AT1 and AA-ACE2 an-
tibodies at the time of diagnosis in COVID-19 patients relative to 
non-infected controls, and whether levels of these autoantibodies at 
diagnosis are associated with mild, moderate and severe COVID-19 
outcome determined at medical discharge on the basis of WHO Clin-
ical Progression Scale. 
2. Methods 
2.1. Study design 
In the present study, a total of 23 adult non-infected controls and 119 
adult patients testing positive for SARS-CoV-2 RT-PCR were included. 
Controls were recruited from users of a dental clinic at the Primary 
Health-Care Unit Fontiñas (Santiago de Compostela). COVID-19 patients 
were prospectively recruited from April 2020 to December 2020 at 
University Hospital Complex of Santiago de Compostela. The sample 
size per group was calculated assuming a minimum large effect size in f- 
test of 0.4 between any pair of groups (n = 4) [17] and accepting an 
alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test. A minimum 
number of 20 subjects is necessary in each group to recognize statisti-
cally significant differences. It has been anticipated a missing data rate 
of 10% due to incomplete primary endpoints. This calculation was 
carried out using the PWR package [18] in R [19]. Patient’s re-
quirements to be recruited were a positive RT-PCR for SARS-CoV-2; to 
be older than 18 years old and to sign an informed consent (designed for 
this purpose). At the time of recruitment, a blood sample was obtained, 
and serum was separated by centrifugation at 1500g for 20 min. Then, 
aliquots of serum samples were stored at − 80 ◦C until processed for 
quantification of AA-AT1, AA-ACE2 and LIGHT levels. Clinical outcome 
of patients was followed until medical discharge, and finally patients 
were divided into three groups according to WHO Clinical Progression 
Scale [20]: mild, moderate, or severe. Mild disease (scores 1–3; n = 31) 
patients were enrolled from the Emergency Room Department. Samples 
from moderate (scores 4–5; n = 68) and severe (scores 6–10; n = 20) 
hospitalized patients were initially obtained from the Emergency Room 
Department before hospitalization. Samples were also obtained from the 
University Hospital Complex of Santiago de Compostela Biobank and 
from Murcian Institute for Biosanitary Research Biobank. All patients 
were followed-up with electronic health information system until 
January 2021. Clinical data assessing demographics, comorbidities, 
symptoms, physical and radiological findings, disease stage, treatment 
and laboratory tests results were collected from electronic medical re-
cords. The study was approved by the Galician Drug Research Ethics 
Committee (CEIm-G), protocol 2020/212. The research was carried out 
in accordance with the principles of the Helsinki Declaration. 
2.2. Serum samples and anti-AT1 and anti-ACE2 autoantibody 
measurements 
Serum samples were stored at − 80 ◦C until the biochemical analysis. 
Serum AA-AT1 and AA-ACE2 were measured using two specific solid- 
phase, sandwich enzyme-linked immunosorbent assays (ELISAs) for 
quantitative determination of these autoantibodies (Catalog Number 
12000 and 16000, respectively; Cell Trend; Luckenwalde, Germany). 
Manufacturer’s instructions were strictly followed. Absorbance was 
measured at 450/620 nm using an Infinite M200 multiwell plate reader 
(TECAN) and AA-AT1 and AA-ACE2 concentrations were quantified 
using specific standard curves from each one (4PL curve fit). In both 
cases, samples with values over the standard curve were diluted with 
assay buffer to get their absorbances within the standard curve. 
2.3. LIGHT/TNFSF14 determination 
To analyse the serum concentration of TNFSF14, also known as 
LIGHT, a commercially available specific ELISA Kit was used (EH 
TNFSF14, Invitrogen) according to the manufacturer’s instructions. 
Protein levels were quantified using specific standard curve (4PL curve 
fit). 
2.4. Statistical analysis 
Data were expressed as median (interquartile range [IQR]). To test if 
the populations follow a normal distribution, Shapiro–Wilk test was 
used. Two group comparisons were carried out by two tailed t-test and 
multiple comparisons by one-way ANOVA followed by post-hoc t-tests. 
When normality assumption was violated, Wilcoxon test for two group 
comparisons and Kruskal-Wallis test followed by post-hoc Mann-Whit-
ney U tests for multiple comparisons were used. Bonferroni correction 
for multiple comparisons was used on post-hoc p-values. When two 
response variables were present, two-way ANOVA were used if dataset 
passed the normality test and for nonparametric data, an Aligned Rank 
Transformation (ART) step was performed before the ANOVA test. 
Spearman’s correlation coefficient (r) was used to study the correlation 
between different parameters. Associations between categorical vari-
ables were tested by using the chi-square test or the Fisher’s exact test if 
expected value is less than 6 in a cell of the contingency table. P < 0.05 
was considered significant for all the analyses. All the analyses were 
done using R software [19]. 
3. Results 
3.1. Patient characteristics 
A total of 23 controls (mean age: 66.13 years old ±6.77 SD; range 
55–76 of which 14 were women and 9 men) and 119 COVID-19 patients 
were enrolled in the study. The patient group included 31 mild, 68 
moderate and 20 severe patients, considering the clinical course of the 
disease at their medical discharge (Table 1). The severe group included 
16 patients who required mechanical or non-invasive ventilation (scores 
6–9) and 4 patients who died (score 10). Mean age of patients was 56.5 
years old (56.5 ± 14.9 SD; range 20–93) and 48.3% were males. The 
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most relevant comorbidities in patient’s group included hypertension 
(33.8%), diabetes (12.8%), dyslipidemia (38.5%), obesity (35.3%), 
heart disease (7.6%), lung disease (8.2%) and renal disease (2.7%). Main 
clinical features are presented in Table 1. No significant differences in 
frequency of comorbidities were observed between control group and 
COVID-19 group. Relationships between COVID-19 severity and 
different comorbidities were studied using chi-square test or Fisher’s 
exact test (see Methods). A significant association (X2Pearson (2) = 7.82; 
p = 0.020) was found between severity and diabetes; severity and 
obesity (X2Pearson (2) = 13.92; p = 0.001) and severity and former 
smokers (X2Pearson(2) = 6.56; p = 0.038). 
3.2. Serum anti-AT1 and anti-ACE2 autoantibodies 
Blood samples from controls and COVID-19 patients were analysed 
to determine serum AA-AT1 and AA-ACE2. Median of AA-AT1 concen-
trations were 5.070 [Interquartile range (IQR) 3.775–8.170] U/mL for 
the control group and 8.209 [IQR 6.006–10.061] U/mL for COVID-19 
patients. Median of AA-ACE2 concentrations were 4.691 [IQR 
2.841–9.863] U/mL in the control group and 9.403 [IQR 4.485–21.552] 
U/mL for COVID-19 patients. Two-way ART-ANOVA analysis revealed 
significantly higher serum levels for AA-AT1 (p = 0.002) and for AA- 
ACE2 (p = 0.013) in COVID-19 group than in the control group. How-
ever, no significant differences were detected between males and fe-
males for serum levels of AA-AT1 (p = 0.845) and AA-ACE2 (p = 0.342) 
when sex differences were tested together with controls/patients, being 
the interaction terms not significant for both levels of autoantibodies. 
(Fig. 1A and B). 
Then, we compared results from the three groups of patients with 
different severity. We observed significant differences, demonstrating 
association between disease severity and serum AA-AT1 and AA-ACE2 
(Fig. 2A and B; Supplementary Table 1). For the analysis of AA-AT1 
and AA-ACE2 we used a Kruskal-Wallis comparison. Mild disease pa-
tients had significantly lower levels of AA-AT1 and AA-ACE2 than 
moderate and severe patients (Mild: AA-AT1 Median 4.627 [IQR 
3.857–9.529] U/mL and AA-ACE2 Median 3.588 [IQR 2.124–9.076] U/ 
mL; Moderate patients: AA-AT1 Median 8.387 [IQR 6.852–10.300] U/ 
mL and AA-ACE2 Median 9.895 [IQR 5.428–26.585] U/mL; Severe 
patients: AA-AT1 Median 8.705 [IQR 6.687–10.158] U/mL and AA- 
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Chronic Respiratory disease  
• Yes 3 (9.7%) 2 (2.9%) 2 (10%) 7 (5.9%) 0.217  









disease       
• Yes 0 (0.0%) 3 (4.4%) 1 (5.3%) 4 (3.4%) 0.485  







(96.6%)   
Fig. 1. Levels of AA-AT1 and AA-ACE2 in controls and COVID-19 patients. COVID-19 patients had significantly higher serum levels of AA-AT1 (A; two-way ART- 
ANOVA, p = 0.002) and AA-ACE2 (B; two-way ART-ANOVA, p = 0.013) than the control group. However, no significant differences were detected between males 
and females for serum levels of AA-AT1 (two-way ART-ANOVA, p = 0.845) and AA-ACE2 (two-way ART-ANOVA, p = 0.342). Interaction terms were not significant 
for both levels of antibodies. Data distribution is shown using a box plot with boxes representing the IQR and the median (black line) and whiskers representing ±1.5 
IQR. IQR: Interquartile range. 
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ACE2 Median 19.597 [IQR 9.306–39.471] U/mL). 
The correlation coefficient between AA-AT1 and AA-ACE2 was sta-
tistically significant; however, it is too low to consider that there is a 
relevant correlation between these variables and suggests that other 
major factors contribute to the increase observed in serum AA-ACE2 
levels (see Discussion). Sex differences were studied together with 
severity (Fig. 2C and D; Supplementary Table 1). However, no signifi-
cant differences were detected in our patients between males and fe-
males for serum levels of AA-AT1 (two-way ART-ANOVA coefficient, p 
= 0.95) and AA-ACE2 (two-way ART-ANOVA coefficient, p = 0.14). 
3.3. RAS autoantibodies and comorbidities associated to COVID-19 
patients 
In order to know whether the increase in autoantibodies observed in 
our patients could be related to comorbidities potentially affecting 
COVID-19 severity, serum levels of AA-AT1 and AA-ACE2 were studied 
in different comorbidities (Wilcoxon-Mann-Whitney test). However, 
only AA-ACE2 levels were significantly higher in patients with diabetes 
(Median 16.630 [IQR 10.480–27.356] U/mL) than in non-diabetic pa-
tients (Median 7.957 [IQR 4.339–19.715] U/mL) (Table 2 and Fig. 3A). 
Moreover, we studied the possible relationship between COVID-19 
Fig. 2. Levels of AA-AT1 and AA-ACE2 in patients with different levels of COVID-19 disease severity. Mild disease patients had significantly lower levels of AA-AT1 
(A) and AA-ACE2 (B) than moderate and severe patients (Kruskal–Wallis one-way analysis of variance on ranks followed by Wilcoxon test). In the present study, no 
significant differences were detected between females and males for serum levels of AA-AT1 (C; two-way ART-ANOVA, p = 0.95) and AA-ACE2 (D; two-way ART- 
ANOVA, p = 0.14) in any of the severity levels of the disease. Data distribution is shown using a box plot with boxes representing the IQR and de median (black line) 
and whiskers representing ±1.5 IQR. IQR: Interquartile range. 
Table 2 
Statistical analysis for AA-AT1 and AA-ACE2 in different comorbidities.   
AA-AT1 (Mann-Whitney test) AA-ACE2 (Mann-Whitney test)  
Statistic p-value Signif Statistic p-value Signif 
Obesity 1707 0.61871 ns 1702 0.63844 ns 
Hypertension 2325 0.76768 ns 2623 0.11398 ns 
Diabetes mellitus 1353 0.46662 ns 1573 0.04669 <0.05* 
Dyslipidemia 2345 0.32846 ns 2668 0.7706 ns 
Smoking 579 0.84562 ns 626 0.44267 ns 
Cardiovascular disease 761 0.8607 ns 813 0.5729 ns 
Chronic Respiratory disease 458 0.20585 ns 350 0.9019 ns 
Chronic kidney disease 332 0.60699 ns 369 0.34116 ns 
Ns: not significant; Signif: Significance. 
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severity and diabetes using chi-square test. A significant association 
(X2Pearson = 7.82; p = 0.020) was found between severity and diabetes. 
Then, we analysed whether the relationship of disease severity and 
autoantibodies was determined by diabetes. However, after controlling 
the possible confounding effect of diabetes by performing a two-way 
ART-ANOVA the relationship of antibodies and disease severity was 
still significant (F(2) = 17.505, p < 0.001). 
Finally, we investigated the possible involvement of LIGHT 
(TNFSF14) in the increase in AA-AT1 observed in the present study. As 
commented below, considerable evidence supports the role for LIGHT in 
generation of AA-AT1 in other diseases. Consistent with this, a signifi-
cant positive correlation between serum levels of AA-AT1 and LIGHT 
was observed (rPearson = 0.70, p < 0.001). Furthermore, a significant 
linear correlation was shown when applying a log transformation to the 
levels of AA-AT1 (rPearson = 0.83, p < 0.001) (Fig. 3B). 
4. Discussion 
In the present study, we observed a significant increase in levels of 
AA-AT1 and AA-ACE2 in COVID-19 patients relative to non-infected 
controls. Furthermore, our results show a significant increase in levels 
of AA-AT1 and AA-ACE2 in moderate and severe COVID-19 patients 
relative to patients with mild outcome. Interestingly, levels of AA-AT1 
showed a high correlation with levels of LIGHT. Levels of AA-AT1 
showed a lower correlation with AA-ACE2. The results also suggest 
that increased levels of autoantibodies are related to differences in the 
response to SARS-CoV-2 infection rather than previous patient comor-
bidities. As could be expected, there is some degree of variability in 
levels of antibodies between patients in the same group of severity, 
which is probably related to individual differences in the immunological 
response and effects of some previous comorbidities such as diabetes. 
However, we observed that the relationship of antibodies and disease 
severity was still significant in diabetic patients. 
AT1 receptor autoantibodies were initially identified in preeclampsia 
[21]. More recently, an increase in circulating AA-AT1 has been related 
to several inflammatory diseases and progression of hypertension and 
cardiovascular processes [12,22]. Levels of AA-AT1 in our cohort of 
moderate and severe COVID-19 patients are similar to those reported by 
other authors in some autoimmune diseases such lupus nephritis [23], 
rheumatoid arthritis or Raynaud’s phenomenon [24]. However, higher 
levels of autoantibodies have been reported for systemic sclerosis and 
primary Sjögren’s syndrome [24]. The present results suggest that 
AA-AT1 contribute to COVID-19 severity, as AA-AT1 bind AT1 receptors 
and, together with Angiotensin II, increase the activity of the RAS 
pro-inflammatory axis (summarized in Fig. 4). It has been shown that 
Ang II enhances severity of several SARS experimental models, which is 
reduced by AT1 blockers [8,10]. In a recent study, we have observed 
that AT1 blockers (i. e. ARAII, ARBs, sartans) increased levels of trans-
membrane ACE2 in the lung while decreased internalization of viral 
spike protein by several mechanisms [10]. The present results suggest 
that patients with high levels of AA-AT1 are particularly suitable can-
didates to treatment with AT1 receptor blockers, which have been 
considered beneficial for COVID-19 outcome in several recent studies 
[25–27]. Increasing evidence indicates that treatments with AT1 re-
ceptor blockers should not be discontinued in patients with COVID-19 or 
at risk of COVID-19. Now, the question is if we should initiate treatment 
with AT1 blockers after COVID-19 diagnosis or in patients at risk of 
infection or risk of severity. Although the above-mentioned experi-
mental and clinical studies suggest beneficial effects, additional clinical 
studies, specifically addressing this question, are necessary. 
Both experimental [28,29] and clinical [30,31] studies have shown 
that the increase in levels of cytokines such as IL-6 and TNF-α in 
COVID-19 plays a major role in the severity of the disease. It has also 
been shown that infusion of IL-6 and TNF-α in animal models induces an 
increase in levels of AA-AT1 [14,15]. However, TNFSF14 (LIGHT) ap-
pears particularly interesting. Circulating LIGHT is mainly secreted by 
cells of the innate and adaptive immune system, although can also be 
produced by tissue structural cells [32,33]. LIGHT acts on structural and 
inflammatory cells to promote initiation of inflammatory and fibrotic 
responses and induces expression of several pro-inflammatory media-
tors, including the above-mentioned cytokines [34], so that LIGHT plays 
a major role in lung tissue remodeling, inflammation and fibrosis [35]. It 
is particularly remarkable that LIGHT, acting via tissue trans-
glutaminase 2 (TG2), has been revealed as a major mechanism for 
generation of AA-AT1. TG2 modifies and stabilizes AT1 receptors [16, 
36], and the epitope sequence of AA-AT1 on the second extracellular 
loop of the receptor can be crosslinked to TG2 via glutamine residue 
Q187 [37]. TG2-modified AT1 receptors act as neoantigens that pro-
mote AA-AT1 generation [16] and AT1 receptor sensitization [38]. 
Consistent with this, we observed a significant correlation between 
AA-AT1 and LIGHT levels in COVID-19 patients. 
A reduction in ACE2 activity at the cell surface (i. e. transmembrane 
ACE2) shifts the RAS balance towards the pro-inflammatory axis, as 
ACE2 transforms Ang II into the anti-inflammatory Ang 1–7. The 
Fig. 3. Levels of AA-ACE2 in COVID-19 patients with and without diabetes and correlation between AA-AT1 levels and LIGHT levels. AA-ACE2 levels (A) were 
significantly higher in patients with diabetes than in non-diabetic patients. Even after controlling the possible confounding effect of diabetes, the relationship of 
antibodies and disease severity was still significant. Data distribution is shown using a box plot with boxes representing the IQR and the median (black line) and 
whiskers representing ±1.5 IQR. *p < 0.05 relative to non-diabetic group (Wilcoxon-Mann-Whitney test). IQR: Interquartile range. AA-AT1 levels positively 
correlated with LIGHT levels (B). Scatterplot showing positive and linear association (rPearson = 0.83, CI95% = [0.74, 0.89]; p < 0.001) between AA-AT1 levels and 
LIGHT levels. The distribution of the variables is shown in the histograms. CI: Confidence Interval. 
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presence of SARS-CoV-2 infection increases the shift towards the RAS 
pro-inflammatory axis. It is known that binding of SARS-CoV-2 to ACE2 
reduces levels of transmembrane ACE2 and induces virus internalization 
and shedding of ACE2 into a soluble/circulating form, as a result of 
activation of the proteases such ADAM17 (TACE, TNF-α -converting 
enzyme) and TMPRSS (transmembrane protease serine 2) [39,40]. 
Activation of the pro-inflammatory AT1 receptors also increases 
ADAM17 and TMPRS activity, increasing viral entry and ACE2 shedding 
[29,41,42]. In the case of COVID-19, generation of AA-ACE2 may be 
enhanced by the presence of circulating immunocomplexes of ACE2- 
SARS-CoV-2 as a consequence of increased levels of circulating ACE2, 
due to virus-induced ACE2 shedding, and the presence of high levels of 
circulating viruses. The presence of high levels of AA-ACE2 may lead to 
further decrease in transmembrane ACE2 activity in the lung and other 
tissues. Therefore, both AA-AT1 (by agonistic stimulation of AT1) and 
AA-ACE2 (by a decrease in transmembrane ACE2 activity and a reduc-
tion of conversion of Ang II into Ang 1–7) lead to increase in AT1 re-
ceptor activity, enhancing the pro-inflammatory responses, and possibly 
viral internalization and ACE2 shedding [29,41,42], and a more severe 
outcome of the COVID-19 disease (Fig. 4). 
Our study has some limitations. A first limitation of the study is the 
relatively low sample size. Severity groups were not balanced, as most of 
the patients belong to the moderate group. Another limitation of this 
study is that we cannot exclude any possible influence of anti-COVID-19 
medications in clinical outcomes, but most of the patients from the same 
severity group received similar treatments. The cross-sectional meth-
odology cannot determine causality but association, and we did not 
include changes in levels of autoantibodies with time. However, we 
were particularly interested in the association between early (i. e. at 
diagnosis) levels of autoantibodies and prediction of severity of the 
disease. Additional measurements during the course of the disease 
would also be interesting. This may be possible in hospitalized patients. 
However, patients of the mild group were sent home for quarantine, and 
sequential measurements are practically impossible in this group. In a 
group of severe or moderate patients with several autoantibody mea-
surements, we did not observe significant changes between samples 
during the disease course. Consistent with this, it was observed that the 
increase in AA-AT1 levels in preeclampsia usually declines 50% by a 
week after delivery [43], and persists in patients for more than 1 year 
postpartum [44]. In a more recent study, circulating AA-AT1 were found 
5–8 years after delivery in women with preeclampsia, [45]. 
5. Conclusions 
The present results suggest that both AA-AT1 and AA-ACE2 
contribute to increase in severity of COVID-19 outcome and could be 
used as an index of probable progression of COVID-19 towards severity. 
Patients with high levels of autoantibodies require more cautious con-
trol after diagnosis of COVID-19. In addition, the results encourage 
further studies on the possible protective treatment with AT1 receptor 
blockers in COVID-19. Finally, the present results also reveal the need 
for further studies where the reported findings are associated with in- 
depth immunological investigations, characterizing adaptive and 
innate immune responses in different COVID-19 phases. 
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Fig. 4. Proposed model for AA-AT1 and AA-ACE2 effects. SARS-CoV-2 infec-
tion induces increase in pro-inflammatory cytokines, particularly LIGHT, pro-
moting AA-AT1, which act as AT1 receptor agonists and enhance the pro- 
inflammatory RAS axis. SARS-CoV-2 binds cell surface ACE2 leading to a 
decrease in this transmembrane ACE2 and an increase in levels of soluble/ 
circulating ACE2. A decrease in transmembrane ACE2 further enhances the pro- 
inflammatory RAS axis and reduces anti-inflammatory axis activity. The in-
crease in levels of circulating ACE2-SARS-CoV-2 complexes may increase levels 
of AA-ACE2, which further reduce transmembrane ACE2 activity and the anti- 
inflammatory RAS function. Green lines, beneficial effects; red lines, detri-
mental effects. 
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Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.jaut.2021.102683. 
Abbreviations 
AA-ACE2 autoantibodies against ACE2 
AA-AT1 autoantibodies for angiotensin type-1 receptors 
ACE2 Angiotensin converting enzyme 2 
ADAM17, TACE, TNF-α converting enzyme; Ang, angiotensin 
AT1 angiotensin type 1 receptors 
ELISA enzyme-linked immunosorbent assay 
IQR Interquartile range 
RAS renin-angiotensin system 
TG2 transglutaminase 2 
TMPRSS transmembrane protease serine 2 
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